Hydromorphone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Hydromorphone

more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
Habitrol
Halcion
Haldol
Haloperidol
Halothane
Heparin sodium
Hepsera
Herceptin
Heroin
Hetacillin
Hexachlorophene
Hexal Diclac
Hexal Ranitic
Hexetidine
Hibiclens
Histidine
Hivid
HMS
Hyalgan
Hyaluronidase
Hycodan
Hycomine
Hydralazine
Hydrochlorothiazide
Hydrocodone
Hydrocortisone
Hydromorphone
Hydromox
Hydroxycarbamide
Hydroxychloroquine
Hydroxystilbamidine
Hydroxyzine
Hyoscine
Hypaque
Hytrin
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Overview

Hydromorphone is a drug used to relieve moderate to severe pain. Hydromorphone is known by the trade names Dilaudid® and Palladone®. It belongs to a category of drugs known as opioid agonists. It is commonly given to patients who have recently undergone surgery or who have suffered serious injury, and it is given intravenously, intramuscularly, rectally, or orally. Hydromorphone is often sought after by opiate drug abusers as it is one of the most potent of all prescription narcotics.

Details

Hydromorphone, a semi-synthetic μ-opioid agonist, is a hydrogenated ketone of morphine and shares the pharmacologic properties typical of opioid analgesics. Hydromorphone and related opioids produce their major effects on the central nervous system and gastrointestinal tract. These include analgesia, drowsiness, mental clouding, changes in mood, euphoria or dysphoria, respiratory depression, cough suppression, decreased gastrointestinal motility, nausea, vomiting, increased cerebrospinal fluid pressure, increased biliary pressure, pinpoint constriction of the pupils, increased parasympathetic activity and transient hyperglycemia. When injected, particularily intravenously, hydromorphone produces more intense contraction sensation in the muscles and a more powerful 'rush' than other opioids, even more so than heroin (diacetylmorphine).

CNS depressants, such as other opioids, anesthetics, sedatives, hypnotics, barbiturates, phenothiazines, chloral hydrate and glutethimide may enhance the depressant effects of hydromorphone. MAO inhibitors (including procarbazine), first-generation antihistamines (brompheniramine, promethazine, diphenhydramine, chlorpheniramine), beta-blockers and alcohol may also enhance the depressant effect of hydromorphone. When combined therapy is contemplated, the dose of one or both agents should be reduced.

Side Effects

Adverse effects of hydromorphone are similar to those of other opioid analgesics, and represent an extension of pharmacological effects of the drug class. The major hazards of hydromorphone include respiratory and CNS depression. To a lesser degree, circulatory depression, respiratory arrest, shock and cardiac arrest have occurred. The most frequently observed adverse effects are sedation, nausea, vomiting, constipation, lightheadedness, dizziness and sweating.

Read more at Wikipedia.org


[List your site here Free!]


Fast-absorbing polyglactin 910 sutures decrease pain
From OB/GYN News, 11/15/05 by Jane Salodof MacNeil

SCOTTSDALE, ARIZ. -- Perineal repairs involving fast-absorbing polyglactin 910 sutures resulted in less pain and earlier resumption of sexual intercourse for new mothers in a randomized, controlled trial comparing the material with standard polyglactin 910 and chromic catgut.

Patients repaired with fast-absorbing polyglactin 910 sutures consumed fewer doses of analgesia and narcotics within 36-48 hours of giving birth. Two-thirds had resumed sexual intercourse at 6 weeks, and 48% had a pain-free experience, investigator Emmanuel Bujold, M.D., said at the annual meeting of the Central Association of Obstetricians and Gynecologists.

Only 42% of women repaired with chromic catgut sutures and 56% with standard polyglactin 910 resumed intercourse at 6 weeks. Just 27% in the chromic catgut cohort and 42% in the standard polyglactin 910 group said intercourse was pain free.

"The benefits of fast-absorbing polyglactin 910 include less short-term perineal pain and probably a shorter time to resumption of pain-free sexual intercourse," said Dr. Bujold of Ste. Justine Hospital and the University of Montreal.

Dr. Bujold and coinvestigator Nathalie Leroux, M.D., also of the University of Montreal, undertook the study to see if the fast-absorbing form of polyglactin 910 could offer the benefits of a synthetic suture without the problems associated with delayed absorption of sutures.

He described suture-related discomfort as very common, with 85% of women suffering some form of perineal trauma in spontaneous vaginal birth. Medical literature reports as many as 69% require sutures, according to the investigators. Most patients suffer perineal pain after delivery, and about a fifth have long-term problems.

The study enrolled women with uncomplicated pregnancies early in labor. Those who had an uncomplicated median episiotomy or a second-degree perineal tear were randomized to sutures made with the three materials; 66 to chromic catgut, 60 to standard polyglactin 910, and 66 to fast-absorbing polyglactin 910.

The well-balanced groups contained women 30 years old on average. More than half of the standard polyglactin 910 cohort and two-thirds of the other cohorts were nulliparous. More than 40% in each group required an episiotomy. About one in four had dyspareunia before pregnancy.

Investigators used a standard analgesia protocol: 50 mg of immediate-release indomethacin and 500 mg of naproxen every 12 hours for 24 hours. As-needed doses were standardized at 500 mg of naproxen every 12 hours, 30 mg of codeine plus 325 mg of acetaminophen, and 1 mg of hydromorphone.

Nurses doing postpartum pain assessments were blinded to the sutures used. Neither pain questionnaire nor visual analog scale scores showed significant differences in evaluation of perineal pain 36-48 hours after the women had given birth.

The median number of analgesic doses was seven with chromic catgut, eight with standard polyglactin 910, and six with fast-absorbing polyglactin 910. Narcotic doses averaged one with chromic catgut and two with standard polyglactin 910 but zero with fast-absorbing polyglactin 910.

At 6 weeks, the number of women for whom data were available had fallen to 53 of the women treated with chromic catgut, 43 with standard polyglactin 910, and 58 with fast-absorbing polyglactin 910.

The data on return to sexual intercourse and pain-free sexual intercourse were significant only when chromic catgut and fast-absorbing polyglactin 910 were compared. At 3 months postpartum, fast-absorbing polyglactin 910 still showed a slight advantage but it was not significant.

Stephen H. Cruikshank, M.D., of Wright State University in Dayton, Ohio, praised the investigators for "a simple but most effective study," which received the association's Central Prize Award. Dr. Cruikshank, the association's new president, said, "It just goes to show us sometimes the most effective study is the simplest."

BY JANE SALODOF MACNEIL

Southwest Bureau

COPYRIGHT 2005 International Medical News Group
COPYRIGHT 2005 Gale Group

Return to Hydromorphone
Home Contact Resources Exchange Links ebay